Targeting DNA repair mechanisms in cancer therapy: the role of small molecule DNA repair inhibitors
NAR Cancer · 07.10.2025 · 7 (4)
DOI: 10.1093/narcan/zcaf040 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift NAR Cancer, online erschienen am 03.11.2025. Verfasst von Seula Jeong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Genomic Integrity, Institute for Basic Science, Ulsan 44919, Republic of Korea. Hauptthemen laut MEDLINE: DNA Repair, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institute for Basic Science.
Abstract (Originalsprache)
Genomic instability and the accumulation of DNA damage are hallmarks of cancer, often resulting from defects in DNA repair pathways. While normal cells rely on highly coordinated DNA damage response (DDR) mechanisms to maintain genomic integrity, cancer cells exploit aberrant DDR regulation to sustain uncontrolled proliferation and survival. Despite significant advancements in chemotherapy, targeted therapy, and immunotherapy, the emergence of resistance remains a major challenge in cancer treatment. Small molecule inhibitors targeting key DDR proteins have emerged as promising therapeutic agents, not only as direct anticancer drugs but also as indispensable tools for dissecting the molecular intricacies of DNA repair. Recent therapeutic approaches leverage synthetic lethality and DDR pathway vulnerabilities to selectively eradicate tumor cells while minimizing damage to normal tissues. These inhibitors provide insights into mechanisms of tumor resistance, facilitating the rational design of combination therapies to enhance treatment efficacy. This review examines the latest advancements in DNA repair-targeted therapeutics, with a focus on small molecule inhibitors currently under clinical investigation. Additionally, we discuss emerging strategies for optimizing DDR-targeted interventions, including biomarker-driven patient selection and rational drug combinations. Understanding these molecular interactions will contribute to the development of novel, more effective treatment paradigms for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Genomic Integrity, Institute for Basic Science, Ulsan 44919, Republic of Korea.
- Department of Biomedical Engineering, Ulsan National Institute of Science and Technology, Ulsan 44919, Republic of Korea.
ORCID-Profile: Seula Jeong, Yuheon Chung, Soomin Heo, Kyungjae Myung
Förderung
- Institute for Basic Science
Zitieren
APA
Jeong, S., Chung, Y., Heo, S., & Myung, K. (2025). Targeting DNA repair mechanisms in cancer therapy: the role of small molecule DNA repair inhibitors. NAR Cancer, 7(4). https://doi.org/10.1093/narcan/zcaf040
Vancouver
Jeong S, Chung Y, Heo S, Myung K. Targeting DNA repair mechanisms in cancer therapy: the role of small molecule DNA repair inhibitors. NAR Cancer. 2025;7(4). doi:10.1093/narcan/zcaf040
BibTeX
@article{Jeong2025,
author = {Jeong, Seula and Chung, Yuheon and Heo, Soomin and Myung, Kyungjae},
title = {Targeting DNA repair mechanisms in cancer therapy: the role of small molecule DNA repair inhibitors},
journal = {NAR Cancer},
year = {2025},
volume = {7},
number = {4},
doi = {10.1093/narcan/zcaf040}
}
EUVIMED